Clinical Trial Update: Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Brentuximab Vedotin as pre-transplant induction and consolidation in relapsed or refractory classical Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: CLASSICAL HODGKIN LYMPHOMA | Phase 1, Phase 2 | Status: COMPLETED